Lifecycle management of orphan drugs approved in Japan

BACKGROUND: The development of orphan drugs (ODs) is challenging from both development and business perspectives because of their small patient populations. To overcome such business challenges, lifecycle management (LCM), which maximizes profits by increasing sales and extending product lifetimes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Seki, Kiyoshi, Suzuki, Hiroshi, Abe, Seiji, Saotome, Chikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336109/
https://www.ncbi.nlm.nih.gov/pubmed/35906686
http://dx.doi.org/10.1186/s13023-022-02456-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336109/
https://www.ncbi.nlm.nih.gov/pubmed/35906686
http://dx.doi.org/10.1186/s13023-022-02456-w

Ejemplares similares